USPTO serial 79346494
CDEMO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 7, 2023
- Examiner
- LAVACHE, LINDA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CDEMO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Govinda M. Davis
Govinda M. Davis Dinsmore & Shohl LLP255 E Fifth Street, Suite 1900Cincinnati, OH 45202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological tissue cultures, other than for medical or veterinary purposes; preparations of microorganisms, other than for medical and veterinary use; reagents for scientific or medical research use; cell growth media for growing cells for use in scientific research; biochemical preparations, namely, monoclonal antibodies for scientific purposes; markers being biological preparations for analyzing proteins for scientific or laboratory purposes; reagents for analyzing proteins for scientific or laboratory purposes; protein preparations for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes; nucleic acid preparations for scientific or laboratory purposes; buffer solutions for scientific purposes; cultures of microorganisms for scientific or laboratory purposes; cells for scientific or laboratory purposes; cultures of microorganisms for character change for scientific or laboratory purposes | ACTIVE | — |
| 005 | Biosimilar pharmaceuticals for the treatment of cancer and prevention of viruses; human immune globulin for the treatment of cancer and prevention of viruses; antibodies for medical purposes for treatment of viral and infectious diseases; pharmaceutical preparations, namely, immunomodulators for the treatment of cancer and prevention of viruses; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceuticals for the treatment of cancer and prevention of viruses; pharmaceutical compositions for the treatment of cancer and prevention of viruses; pharmaceutical biosimilars for human use for the treatment of cancer and prevention of viruses; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for the treatment of cancer; biosimilar pharmaceuticals for the treatment of cancer; human vaccine preparations; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; viral vaccines; pharmaceutical products for the treatment of viral diseases; anti-viral agents | ACTIVE | — |
| 040 | Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials, namely, processing of biopharmaceutical materials; processing of pharmaceutical preparations; custom manufacture of pharmaceuticals; preservation of pharmaceuticals; processing of medical products, namely, chemical processing of pharmaceuticals; processing of chemicals; chemical treatment of liquid pharmaceutical preparations; chemical processing of medicinal materials | ACTIVE | — |
| 042 | Development of biologics; design of biologics; research of biologics; research and development services in the field of engineering; providing advice in the field of technological research relating to pharmaceutical manufacturing process technology; scientific and technological services, namely, scientific research, medical and scientific research, pharmaceutical screening for scientific research purposes, biological research; development of industrial processes; industrial process research in the field of pharmaceuticals and biological research; research relating to the computerised automation of technical processes; research relating to the computerised automation of industrial processes; quality control for others; process monitoring for quality assurance in the field of pharmaceuticals; research and development of devices for chemical processing; research and development of pilot equipment for chemical processing; consultancy in the field of engineering; providing consultation, advice, and information in the field of engineering research; product research and development in the fields of products for the treatment of viral and infectious diseases, products for the treatment of cancer, viral vaccines, pharmaceutical products for the treatment of viral diseases, and anti-viral agents | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Prestige Biologics Co., Ltd.
- Other trademarks owned by Prestige Biologics Co., Ltd.
- Other trademarks owned by Prestige Biologics Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named CDEMO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 4, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 8, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 8, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 7, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 7, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 7, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 22, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 22, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 2, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 2, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 2, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 17, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 17, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 17, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 17, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 17, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 3, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 2, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 14, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 9, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 5, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 4, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |